Wolfgang Mohl

Saarbruecken, SL, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study.

Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study.

Journal: Journal of Crohn's & colitis

Published: March 28, 2025

Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment.

Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment.

Journal: Journal of Crohn's & colitis

Published: March 25, 2025

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.

Journal: Inflammatory bowel diseases

Published: January 23, 2023

Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.

Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.

Journal: Alimentary pharmacology & therapeutics

Published: December 23, 2022

Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.

Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.

Journal: Inflammatory bowel diseases

Published: June 25, 2022

Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study.

Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study.

Journal: Advances in therapy

Published: February 04, 2022

Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease

Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease

Journal: Zeitschrift fur Gastroenterologie

Published: November 08, 2021

Position paper on endoscopic reporting in IBD

Position paper on endoscopic reporting in IBD

Journal: Zeitschrift fur Gastroenterologie

Published: July 20, 2021

Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study.

Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study.

Journal: International journal of colorectal disease

Published: April 26, 2021

Thumb sucking or nail biting in childhood and adolescence is associated with an increased risk of Crohn's disease: results from a large case-control study.

Thumb sucking or nail biting in childhood and adolescence is associated with an increased risk of Crohn's disease: results from a large case-control study.

Journal: Scandinavian journal of gastroenterology

Published: July 31, 2020

Azathioprine allows glucocorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases.

Azathioprine allows glucocorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases.

Journal: Zeitschrift fur Gastroenterologie

Published: May 13, 2017

Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.

Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.

Journal: Gut

Published: September 29, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026